可孚医疗 reported revenue of ¥2.07B for the period ended 2026-06-30, +38.5% year on year. Net income was ¥0.20B, a 9.8% net margin on a 55.9% gross margin. The largest revenue line is 产品销售 at 97% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.07B | +38.5% |
| Gross profit | ¥1.16B | — |
| Operating income | ¥0.24B | — |
| Net income | ¥0.20B | +21.9% |
| Gross margin | 55.9% | Net margin 9.8% |
| Revenue Q/Q | +4.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 产品销售 | ¥2.02B | 97.3% |
| 其他(补充) | ¥0.06B | 2.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.91B | 44.1% |
| R&D | ¥0.05B | 2.5% |
| SG&A | ¥0.85B | 41.0% |
| Tax & other | ¥0.04B | 2.0% |
| Item | Amount |
|---|---|
| Total assets | ¥7.46B |
| Total liabilities | ¥1.89B |
| Shareholders' equity | ¥5.56B |
| Equity / assets | 74.6% |
| Operating cash flow | ¥0.16B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 129% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药 ・ 天益医疗 ・ 金埔园林 ・ 雅创电子 ・ 风光股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies